Medicenna Therapeutics Reported In-line with Estimates

Medicenna Therapeutics (MDNAF) reported a loss of $0.04 per share on revenue of $0.00 million for the fiscal first quarter ended June 2026. The consensus estimate was a loss of $0.04 per share. The company reported in-line with consensus estimates.

Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.